Alternative Data for Amylyx Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 14 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 12,000 | Sign up | Sign up | Sign up |
| Employee Rating | 78 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 6 | Sign up | Sign up | Sign up |
| Facebook Followers | 822 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 30 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,149 | Sign up | Sign up | Sign up |
| X Followers | 2,897 | Sign up | Sign up | Sign up |
| X Mentions | 8 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 52 | Sign up | Sign up | Sign up |
| Linkedin Employees | 167 | Sign up | Sign up | Sign up |
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases.
| Price | $14.58 |
| Target Price | Sign up |
| Volume | 1,995,366 |
| Market Cap | $1.65B |
| Year Range | $9.95 - $18.36 |
| Dividend Yield | 0% |
| Analyst Rating | 60% buy |
| Industry | Biotechnology |
In the news
Amylyx Pharmaceuticals Q1 Earnings Call HighlightsMay 7 - Yahoo Entertainment |
|
Amylyx Pharmaceuticals (AMLX) Winds Up Avexitide Phase 3 Lucidity Trial EnrollmentMarch 31 - Yahoo Entertainment |
|
B of A Securities Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $19February 19 - Benzinga |
|
HC Wainwright & Co. Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $28February 9 - Benzinga |
|
Amylyx Pharmaceuticals: Back From The DeadJanuary 26 - SeekingAlpha |
|
Pharmaceutical and Biotechnology Royalty Rates Agreements Report and Directory 2026: Insights Into 1,567 Licensing Transactions by Company A-Z, Therapeutic Area, Technology, Headline ValueMarch 12 - GlobeNewswire |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '26 | 0 | 98,000 | -98,000 | -41M | -44M | -0.370 |
| Q4 '25 | 0 | 110,000 | -110,000 | -33M | -31M | -0.300 |
| Q3 '25 | 0 | 20M | -20M | -34M | -34M | -0.370 |
| Q2 '25 | 0 | 140,000 | -140,000 | -41M | -41M | -0.460 |
| Q1 '25 | 0 | 0 | 0 | -36M | -38M | -0.420 |
Insider Transactions View All
| Mazzariello Gina filed to sell 134,430 shares at $14.5. March 4 '26 |
| FRATES JAMES M filed to sell 165,638 shares at $14.5. March 4 '26 |
| Bedrosian Camille L filed to sell 169,295 shares at $14.6. March 4 '26 |
| Cohen Joshua B filed to sell 3,334,683 shares at $14.5. March 4 '26 |
| Klee Justin B. filed to sell 3,334,616 shares at $14.5. March 4 '26 |
Similar companies
Read more about Amylyx Pharmaceuticals (AMLX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Amylyx Pharmaceuticals
The Market Cap of Amylyx Pharmaceuticals is $1.65B.
Currently, the price of one share of Amylyx Pharmaceuticals stock is $14.58.
The AMLX stock price chart above provides a comprehensive visual representation of Amylyx Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Amylyx Pharmaceuticals shares. Our platform offers an up-to-date AMLX stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Amylyx Pharmaceuticals (AMLX) does not offer dividends to its shareholders. Investors interested in Amylyx Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Amylyx Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
